NEW YORK, NY – Enzo Biochem Inc. (NYSE:ENZ) announced the results of its Annual Shareholders Meeting today and updated shareholders on its businesses. Shareholders voted overwhelmingly to re-elect the Company’s nominees, Gregory M. Bortz and Dov Perlysky, as Class I directors to hold office for a term of three years. Shareholders also ratified the selection of EisnerAmper LLP as the Company’s auditors, among other matters.

The Company also provided investors with its plan for developing proprietary molecular diagnostics platforms and assays designed to deliver savings of 30-50% for Labs, and updated investors on its legal strategies, including discussing its $9 million settlement with Agilent Technologies announced earlier today. Apart from detailing the Company’s success in monetizing its intellectual property estate, Mr. Weiner, the Company’s President, also discussed at length Enzo’s strategic plan for molecular diagnostics, which he termed “very exciting and promising.”

Specifically, Mr. Weiner said Enzo is poised to deliver products and services that are high performing, cost-effective and easily adaptable to today’s molecular marketplace, in which clinical labs both nationwide and globally are facing margin pressures despite growth in demand

.

“While the industry is over $5 billion today and growing, with this growth have come unprecedented challenges to the clinical laboratories in the form of margin pressure as increased costs are being met by decreased reimbursements for their services, resulting in losses on each molecular test they provide,” said Mr. Weiner.

“To meet this need, our uniquely integrated structure has enabled us to develop high-performing molecular diagnostic products and services, at savings to the marketplace of 30% to 50%, while providing easily adaptable solutions that will allow labs to utilize them with little or no change to their normal workflow. “

He noted the recent approval by the New York State Department of Health of the AmpiProbe HCV™ test as just the start of a battery of assays under development geared to molecular diagnostics. Mr. Weiner commented: “We are highly encouraged by the response to news of this new assay, and we are making significant progress. We are looking forward to further assay validations for our AmpiProbe™ platform with a pipeline encompassing a number of products, including a panel addressing the women’s health market as well as other infectious diseases. Other platforms that we have developed are expected to yield products in the fields of cancer, immunology and cardiology, to name a few.”

Shareholders were reminded that today’s announced settlement with Agilent impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, eight of which remain pending.

Mr. Weiner noted that over the past five years, Enzo has received more than $65 million in settlements and licensing revenues, well in excess of the Company’s total legal spending in the same period.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.